Skip to main content

Specialty Pharmacy

  • BIO calls for different names for biosimilars, branded biotech drugs

    NEW YORK — In what is emerging as the latest battle over follow-on biologics, a new argument has emerged about what to call them, and supporters of biotechnology companies are the latest to take a shot.

  • Walgreens collects donations for Susan G. Komen

    DALLAS — Walgreens is collecting donations for breast cancer treatment through a partnership with Susan G. Komen to mark National Breast Cancer Awareness Month, which takes place this month.

  • Depomed launches Lazanda nasal spray for breakthrough pain in cancer patients

    NEWARK, Calif. — Depomed has launched a new drug for breakthrough pain in cancer patients, the company said Monday.

    The drug maker announced the launch of Lazanda (fentanyl) nasal spray, meant for treating adults who are taking opioid painkillers, but have become tolerant to them. The company also have launched a Signature Support Program designed to streamline patient access to the drug, including reimbursement and co-pay assistance. Other benefits of the program include prescription reminders and eligibility for one month's supply for free.

  • FDA introduces e-learning program about untruthful, misleading drug ads

    SILVER SPRING, Md. — The Food and Drug Administration has launched an online learning course aimed at healthcare professionals to educate them about potentially untruthful or misleading drug ads and promotional materials.

  • APhA, NACDS, NCPA join biosimilar naming debate

    NEW YORK — Three pharmacy groups are petitioning the World Health Organization to uphold common generic names for biosimilars and their branded reference products.

  • FDA approves first single-entity, extended-release hydrocodone drug

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new opioid painkiller made by Zogenix, the agency said Friday.

    The FDA announced the approval of Zohydro ER (hydrocodone) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long-term treatment. The agency said the drug was the first extended-release hydrocodone product not combined with another drug, such as acetaminophen, to be approved by the agency.

  • FDA Antiviral Drugs Advisory Committee recommends approval for J&J hepatitis C drug

    NEW YORK — A Food and Drug Administration expert panel has recommended approval for a drug made by Johnson & Johnson for treating hepatitis C, the company said.

    J&J subsidiary Janssen Research & Development said the 19-member FDA Antiviral Drugs Advisory Committee voted unanimously to recommend approval for TMC435 (simeprevir), a 150-mg drug meant for administration once per day with the generic antiviral ribavirin and a biotech drug known as an interferon, for treating genotype 1 chronic hepatitis C.

  • All American Pet Co. to sell NutraBars for dogs at Albertsons

    LOS ANGELES — Albertsons has placed an order for what is being called the "first true food bar" for dogs.

    All American Pet Co. said Friday it received an order from the grocer for NutraBars, which are designed to be high in protein and low in fat, and are made in the United States.

    The company said it also was expecting an order for Chewies Dog Treats, which are all-natural and made with peanuts, cheese and bacon. Albertsons, based in Boise, Idaho, operates 1,119 stores under 12 banners in 29 states.

     

X
This ad will auto-close in 10 seconds